Related Experiment Video

Updated: Oct 1, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

New and Old Genes Associated with Topotecan Resistance Development in Ovarian Cancer Cell Lines

Andrzej Klejewski1,2, Monika Świerczewska3, Katarzyna Zaorska3

  • 1Department of Nursing, Poznan University of Medical Sciences, Poznan, Poland aklejewski@ump.edu.pl.

Anticancer Research
|April 5, 2017
PubMed
Abstract

Insights

Drug resistance limits chemotherapy effectiveness in ovarian cancer. This study identified ABCG2 and ABCB1 gene overexpression as key factors in topotecan resistance, crucial for developing new ovarian cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chemotherapy resistance is a major challenge in ovarian cancer treatment.
  • Topotecan is a common second-line chemotherapy agent for ovarian cancer.
  • Understanding the mechanisms of topotecan resistance is critical for improving patient outcomes.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying the development of topotecan resistance in ovarian cancer cell lines.
  • To identify specific genes associated with topotecan resistance.

Main Methods:

  • Ovarian cancer cell lines were treated with topotecan to induce resistance.
  • Chemosensitivity was assessed using the MTT assay.
  • Gene expression levels of ABCB1, ABCG2, ALDH1A1, IFIH1, SAMD4, and EPHA3 were quantified using quantitative polymerase chain reaction (Q-PCR).

Main Results:

  • Topotecan resistance was observed in a dose-dependent manner.
  • Overexpression of ABCG2, IFIH1, and SAMD4 genes was consistently found in topotecan-resistant cell lines.
  • ABCB1 gene expression was detected in one resistant cell line, while ALDH1A1 showed differential regulation.

Conclusions:

  • ABCG2 and ABCB1 gene expression are significantly associated with topotecan resistance in ovarian cancer.
  • These genes are primary drivers of resistance, with other investigated genes playing a secondary role.
Keywords:
Ovarian cancerdrug transportersnew genestopotecan resistance

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...